Arrowhead Pharmaceuticals, Inc.
ARWR
Rangering i aksjer
#2335
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Aksjekurs
$59.25
Sist synkronisert: 2026-10-21
Markedsverdi
$8.37B
Endring (1 dag)
0.56%
Endring (1 år)
57.45%
Land
US
Handel Arrowhead Pharmaceuticals, Inc. (ARWR)
Kategori
Healthcare
Aksjeprishistorikk for Arrowhead Pharmaceuticals, Inc. (ARWR)
Høyeste sluttskurs: $60.32 den 2026-10-01
Laveste sluttskurs: $2.33K den 1993-12-01
Laveste sluttskurs: $2.33K den 1993-12-01
Aksjeprishistorikk for Arrowhead Pharmaceuticals, Inc. fra 1993 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 1.87% |
| 2025 | 208.16% |
| 2024 | -20.53% |
| 2023 | -20.47% |
| 2022 | -50.27% |
| 2021 | -7.77% |
| 2020 | 12.92% |
| 2019 | 400.12% |
| 2018 | 279.40% |
| 2017 | 152.54% |
| 2016 | -76.85% |
| 2015 | -0.51% |
| 2014 | -35.31% |
| 2013 | 321.97% |
| 2012 | -52.26% |
| 2011 | -50.19% |
| 2010 | 68.10% |
| 2009 | -55.50% |
| 2008 | -68.27% |
| 2007 | -13.22% |
| 2006 | 20.92% |
| 2005 | -9.23% |
| 2004 | 136.27% |
| 2003 | 403.07% |
| 2002 | -69.36% |
| 2001 | -72.13% |
| 2000 | 5.98% |
| 1999 | -21.17% |
| 1998 | 22.37% |
| 1997 | -62.29% |
| 1996 | -76.32% |
| 1995 | 222.59% |
| 1994 | -94.15% |
| 1993 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $761.37 | 8.22% |
CH
|
